Dissemination of strongyloides stercoralis in a patient with systemic lupus erythematosus after initiation of albendazole: A case report

被引：15

作者：

Hunter C.J. ^{[1
]}

Petrosyan M. ^{[2
]}

Asch M. ^{[1
]}

机构：

[1] Harbor UCLA Medical Center, Department of Surgery, Torrance, CA 90502, W. Carson Street

[2] University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, North State Street

来源：

Journal of Medical Case Reports | / 2卷 / 1期

关键词：

Systemic Lupus Erythematosus; Celecoxib; Stool Sample; Ivermectin; Albendazole;

D O I：

10.1186/1752-1947-2-156

中图分类号：

学科分类号：

摘要：

Introduction: Strongyloides stercoralis infection affects hundreds of millions of people worldwide. As immigration rates and international travel increase, so does the number of cases of strongyloidiasis in the United States. Although described both in immigrant and in immunosuppressed populations, hyperinfection and dissemination of S. stercoralis following the initiation of antiparasitic medication is a previously unreported phenomenon. Case presentation: Here we describe the case of a 38-year-old immunocompromised woman with systemic lupus erythematosus, who developed disseminated disease following treatment with albendazole (400 mg every 12 hours). Notably the patient was receiving oral prednisone (10 mg once daily), azathioprine (50 mg twice daily), and hydroxychloroquine (400 mg daily) at the time of hospitalization. The patient was subsequently treated successfully with ivermectin (200 mcg/kg daily). Conclusion: The reader should be aware that dissemination of S. stercoralis can occur even after the initiation of antiparasitic medication. © 2008 Hunter et al; licensee BioMed Central Ltd.

引用

共 16 条

[1]

Genta R.M., Global prevalence of strongyloidiasis: Critical review with epidemiologic insights into the prevention of disseminated disease, Rev Infect Dis, 11, 5, pp. 755-767, (1989)

[2]

Walzer P.D., Milder J.E., Banwell J.G., Kilgore G., Klein M., Parker R., Epidemiologic features of Strongyloides stercoralis infection in an endemic area of the United States, Am J Trop Med Hyg, 31, 2, pp. 313-319, (1982)

[3]

Gill G.V., Welch E., Bailey J.W., Bell D.R., Beeching N.J., Chronic Strongyloides stercoralis infection in former British Far East prisoners of war, Qjm, 97, 12, pp. 789-795, (2004)

[4]

Rotman H.L., Yutanawiboonchai W., Brigandi R.A., Leon O., Nolan T.J., Schad G.A., Abraham D., Strongyloides stercoralis: Complete life cycle in SCID mice, Exp Parasitol, 81, 1, pp. 136-139, (1995)

[5]

Patil P., Jayshree R.S., Acharya R.S., Sridhar H., Babu G., Suresh T.M., Fulminant fatal Strongyloides stercoralis infection in a postchemotherapy immunosuppressed cancer patient, Med Pediatr Oncol, 33, 5, pp. 504-505, (1999)

[6]

Makris A.N., Sher S., Bertoli C., Latour M.G., Pulmonary strongyloidiasis: An unusual opportunistic pneumonia in a patient with AIDS, AJR Am J Roentgenol, 161, 3, pp. 545-547, (1993)

[7]

Ghosh K., Ghosh K., Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: Report of three cases, Trans R Soc Trop Med Hyg, (2007)

[8]

Mora C.S., Segami M.I., Hidalgo J.A., Strongyloides stercoralis hyperinfection in systemic lupus erythematosus and the antiphospholipid syndrome, Semin Arthritis Rheum, 36, 3, pp. 135-143, (2006)

[9]

Upadhyay D., Corbridge T., Jain M., Shah R., Pulmonary hyperinfection syndrome with Strongyloides stercoralis, Am J Med, 111, 2, pp. 167-169, (2001)

[10]

Csermely L., Jaafar H., Kristensen J., Castella A., Gorka W., Chebli A.A., Trab F., Alizadeh H., Hunyady B., Strongyloides hyper-infection causing life-threatening gastrointestinal bleeding, World J Gastroenterol, 12, 39, pp. 6401-6404, (2006)

← 1 2 →